{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:33:38Z","timestamp":1791344018337,"version":"4.3.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.leukres.2007.08.004","type":"journal-article","created":{"date-parts":[[2007,9,19]],"date-time":"2007-09-19T11:35:18Z","timestamp":1190201718000},"page":"587-591","source":"Crossref","is-referenced-by-count":111,"title":["Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)"],"prefix":"10.1016","volume":"32","author":[{"given":"P.W.","family":"Wijermans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"R\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Slack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.I.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2007.08.004_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2007.08.004_bib2","series-title":"World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.leukres.2007.08.004_bib3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML)","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2007.08.004_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00277-005-0012-1","article-title":"An epigenetic approach to the treatment of advanced MDS: the experience with the DNA demethylating agent 5-aza-2\u2032-deoxycytidine (Decitabine) in 177 patients","volume":"84","author":"Wijermans","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2007.08.004_bib5","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2007.08.004_bib6","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.08.004_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11864-002-0011-6","article-title":"Chronic myelomonocytic leukemia","volume":"3","author":"Bennett","year":"2002","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.leukres.2007.08.004_bib8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/sj.leu.2402891","article-title":"Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML)","volume":"17","author":"Tessema","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2007.08.004_bib9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3324\/haematol.11051","article-title":"Chronic myelomonocytic leukemia in the light of the WHO proposals","volume":"92","author":"Germing","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2007.08.004_bib10","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.08.004_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0145-2126(97)00149-5","article-title":"Treatment with low dose oral etoposide in patients with myelodysplastic syndromes","volume":"22","author":"Doll","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2007.08.004_bib12","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukaemia. Groupe Francais des Myelodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"issue":"5\u20136","key":"10.1016\/j.leukres.2007.08.004_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199809057611","article-title":"Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"31","author":"Beran","year":"1998","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.leukres.2007.08.004_bib14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/cncr.21699","article-title":"Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2007.08.004_bib15","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2007.08.004_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2007.08.004_bib17","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.2005.05.4346","article-title":"Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921 and 9221 by the Cancerand Leukemia Group","volume":"24","author":"Silverman","year":"2006","journal-title":"Br J Clin Oncol"},{"key":"10.1016\/j.leukres.2007.08.004_bib18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607003220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212607003220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T13:05:15Z","timestamp":1587906315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212607003220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0145212607003220"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2007.08.004","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1091605.546093","asserted-by":"object"}]},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}